BRIEF-MEI Pharma Reports Update From Clinical Study Evaluating Oral CDK9 Inhibitor Voruciclib In Combination With Venetoclax

Reuters03-26

March 26 (Reuters) - MEI Pharma Inc :

* MEI PHARMA REPORTS UPDATE FROM CLINICAL STUDY EVALUATING ORAL CDK9 INHIBITOR VORUCICLIB IN COMBINATION WITH VENETOCLAX IN PATIENTS WITH RELAPSED AND REFRACTORY ACUTE MYELOID LEUKEMIA

* MEI PHARMA INC - ENROLLMENT INITIATED IN 12-PATIENT EXPANSION COHORT EVALUATING VORUCICLIB PLUS VENETOCLAX IN ONGOING PHASE 1 STUDY

* MEI PHARMA INC - ANTI-LEUKEMIC ACTIVITY ACROSS MULTIPLE HEAVILY PRETREATED PATIENTS DEMONSTRATED ALONG WITH ANTICIPATED DECREASES IN MCL-1

* MEI PHARMA INC - NO EVIDENCE OF OVERLAPPING TOXICITY, AND NO DOSE LIMITING TOXICITIES OBSERVED TO DATE IN DOSE ESCALATION COHORTS

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2422615047?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-03-26 21:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2422615047","market":"us","top_or_hot":-1,"title":"BRIEF-MEI Pharma Reports Update From Clinical Study Evaluating Oral CDK9 Inhibitor Voruciclib In Combination With Venetoclax","media":"Reuters","content":"<html><body><p>March 26 (Reuters) - <a href=\"https://laohu8.com/S/MEIP\">MEI Pharma</a> Inc   :</p><p>   * MEI PHARMA REPORTS UPDATE FROM CLINICAL STUDY EVALUATING ORAL CDK9 INHIBITOR VORUCICLIB IN COMBINATION WITH VENETOCLAX IN PATIENTS WITH RELAPSED AND REFRACTORY ACUTE MYELOID LEUKEMIA</p><p>   * MEI PHARMA INC - ENROLLMENT INITIATED IN 12-PATIENT EXPANSION <a href=\"https://laohu8.com/S/CHRT.UK\">COHORT</a> EVALUATING VORUCICLIB PLUS VENETOCLAX IN ONGOING PHASE 1 STUDY</p><p>   * MEI PHARMA INC - ANTI-LEUKEMIC ACTIVITY ACROSS MULTIPLE HEAVILY PRETREATED PATIENTS DEMONSTRATED ALONG WITH ANTICIPATED DECREASES IN MCL-1</p><p>   * MEI PHARMA INC - NO EVIDENCE OF OVERLAPPING TOXICITY, AND NO DOSE LIMITING TOXICITIES OBSERVED TO DATE IN DOSE ESCALATION COHORTS</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-MEI Pharma Reports Update From Clinical Study Evaluating Oral CDK9 Inhibitor Voruciclib In Combination With Venetoclax</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-MEI Pharma Reports Update From Clinical Study Evaluating Oral CDK9 Inhibitor Voruciclib In Combination With Venetoclax\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-03-26 21:49 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>March 26 (Reuters) - MEI Pharma Inc   :   * MEI PHARMA REPORTS UPDATE FROM CLINICAL STUDY EVALUATING ORAL CDK9 INHIBITOR VORUCICLIB IN COMBINATION WITH VENETOCLAX IN PATIENTS WITH RELAPSED AND ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2422615047","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2422615047","pubTimestamp":1711460975,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"March 26  - MEI Pharma Inc   :   * MEI PHARMA REPORTS UPDATE FROM CLINICAL STUDY EVALUATING ORAL CDK9 INHIBITOR VORUCICLIB IN COMBINATION WITH VENETOCLAX IN PATIENTS WITH RELAPSED AND REFRACTORY ACUTE MYELOID LEUKEMIA   * MEI PHARMA INC - ENROLLMENT INITIATED IN 12-PATIENT EXPANSION COHORT EVALUATING VORUCICLIB PLUS VENETOCLAX IN ONGOING PHASE 1 STUDY   * MEI PHARMA INC - ANTI-LEUKEMIC ACTIVITY ACROSS MULTIPLE HEAVILY PRETREATED PATIENTS DEMONSTRATED ALONG WITH ANTICIPATED DECREASES IN MCL-1   * MEI PHARMA INC - NO EVIDENCE OF OVERLAPPING TOXICITY, AND NO DOSE LIMITING TOXICITIES OBSERVED TO DATE IN DOSE ESCALATION COHORTSSource text for Eikon:    Further company coverage:    ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","MEIP":"MEI Pharma","MEI":"Methode Electronics Inc","BK4145":"电子制造服务"},"translate_title":"MEI Pharma报告口服CDK9抑制剂Voruciclib与Venetoclax联合应用的临床研究进展","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MEI":1,"MEIP":1},"content_text":"March 26 (Reuters) - MEI Pharma Inc   :   * MEI PHARMA REPORTS UPDATE FROM CLINICAL STUDY EVALUATING ORAL CDK9 INHIBITOR VORUCICLIB IN COMBINATION WITH VENETOCLAX IN PATIENTS WITH RELAPSED AND REFRACTORY ACUTE MYELOID LEUKEMIA   * MEI PHARMA INC - ENROLLMENT INITIATED IN 12-PATIENT EXPANSION COHORT EVALUATING VORUCICLIB PLUS VENETOCLAX IN ONGOING PHASE 1 STUDY   * MEI PHARMA INC - ANTI-LEUKEMIC ACTIVITY ACROSS MULTIPLE HEAVILY PRETREATED PATIENTS DEMONSTRATED ALONG WITH ANTICIPATED DECREASES IN MCL-1   * MEI PHARMA INC - NO EVIDENCE OF OVERLAPPING TOXICITY, AND NO DOSE LIMITING TOXICITIES OBSERVED TO DATE IN DOSE ESCALATION COHORTSSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2422615047"}